NasdaqGM:KYMRBiotechs
Assessing Kymera Therapeutics (KYMR) Valuation After Strong 3 Month And 1 Year Share Price Gains
Kymera Therapeutics (KYMR) has drawn attention recently, with the stock up about 19.5% over the past 3 months and about 82.7% over the past year. This performance is prompting investors to reassess its profile.
See our latest analysis for Kymera Therapeutics.
That recent 3.86% 1 day share price return, together with a 19.5% 90 day share price return and 82.7% 1 year total shareholder return, points to momentum building around Kymera as investors reassess its risk and growth profile following...